SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
VBI Vaccines announced FDA Acceptance of BLA filing for VBIï¾’s 3-antigen prophylactic hepatitis B vaccine
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
Roche announced launch of SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
NIH study showed hyaluronan effective in treating chronic lung disease
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
Dynavax announced exercise of option to reserve additional CpG 1018 to produce 40 million doses of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…
Pfizer and BioNTech publish preclinical data from investigational COVID-19 vaccine program in Nature
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
The CDC required wearing of face masks while on public transportation and at transportation hubs
On Jan. 30, 2021, as the COVID-19 pandemic continued to surge in the U.S., the CDC implemented a…
Rigel awarded $165 Million from US DOD for phase 3 clinical trial of Fostamatinib in COVID-19 patients
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
Humanigen completed enrollment in phase 3 study of lenzilumab in hospitalized patients with COVID-19
On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab…
Innovation Pharmaï¾’s phase 2 clinical trial of Brilacidin for treating COVID-19 began
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyï¾’s Phase 2 clinical trial of Brilacidin for treating…
Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of phase 3 ENSEMBLE trial
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
Pfizer and BioNTech published data on COVID-19 vaccine-induced antibodiesï¾’ ability to neutralize SARS-CoV-2 UK strain
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
DNA Genotekﾒs OMNIgeneﾮﾷORAL included in EUA granted to Ambry Genetics for use in COVID-19 RT-PCR saliva test
On Jan. 29, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
South Carolina detected first US cases associated with variant first detected in South Africa
On Jan. 28, 2021, the CDC announced that it had become aware of the first U.S. documented cases…
DNA Genotekﾒs OMNIgeneﾮﾷORAL saliva collection device received Health Canada Authorization for COVID-19 testing
On Jan. 28, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary…
Ajinomoto Bio-Pharma and Humanigen expanded agreement to support fill finish for COVID-19 therapeutic
On Jan. 27, 2021, Ajinomoto Bio-Pharma Services and Humanigen announced the companies will be expanding their manufacturing agreement…
OncoSec announced first subjects dosed in phase 1 trial of CORVax12, COVID-19 vaccine candidate
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
Lilly, Vir Biotechnology and GSK announced first patient dosed in expanded BLAZE-4 trial for COVID-19
On Jan. 27, 2021, Eli Lilly, Vir Biotechnology and GlaxoSmithKline announced a collaboration to evaluate a combination of…
Heat Biologics announced publication of additional preclinical COVID-19 vaccine results
On Jan. 27, 2021, Heat Biologics announced the publication of additional preclinical COVID-19 results in Frontiers in Immunology,…
REGEN-COV antibody cocktail Is active against SARS-CoV-2 variants identified in the UK and South Africa
On Jan. 27, 2021, researchers in Dr. David Ho’s Columbia University lab and Regeneron scientists announced they had…
In vitro studies demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with UK and South African Variants
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
Antibody infusions prevented acquisition of some HIV strains, NIH studies found
On Jan. 26, 2021, NIH researchers announced that an investigational anti-HIV antibody delivered intravenously once every eight weeks…
Abbott’s panbio rapid antigen test received CE Mark for asymptomatic screening and sample collection
On Jan. 26, 2021, Abbott announced it had received CE Mark for two new uses of its Panbioï¾™…
NIH launched database to track neurological symptoms associated with COVID-19
On Jan. 26, 2021, NIH researchers announced that a new database to collect information from clinicians about COVID-19-related…
Vaxart announced additional preclinical COVID-19 oral vaccine data and publication
On Jan. 26, 2021, Vaxart announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a…
Data showed Lilly’s neutralizing antibodies bamlanivimab and etesevimab reduced risk of COVID-19 hospitalizations and death by 70 percent
On Jan. 26, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together…
BioReference Laboratories teamed-up with the NBA and NHL to provide players and staff with COVID-19 testing
On Jan. 26, 2021, BioReference Laboratories, an OPKO Health company, announced COVID-19 testing agreements for players and officials,…
Merck discontinued development of SARS-CoV-2/COVID-19 vaccine candidates
On Jan. 25, 2021, Merck announced that the company had discontinued development of its SARS-CoV-2/COVID-19 vaccine candidates, V590…